메뉴 건너뛰기




Volumn 23, Issue 2, 2012, Pages 463-471

Corrigendum: Phase i safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors (Annals of Oncology (2012) 23 (463-471) DOI: 10.1093/annonc/mdr137);Phase i safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors

Author keywords

Biomarker; Clinical trial; pan HER inhibitor; Phase I study

Indexed keywords

4 [1 (3 FLUOROBENZYL) 5 INDAZOLYLAMINO] 5 METHYLPYRROLO[2,1 F][1,2,4]TRIAZINE 6 CARBAMIC ACID 3 MORPHOLINOMETHYL ESTER; AC 480; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FAMOTIDINE; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

EID: 84856331314     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdy532     Document Type: Erratum
Times cited : (20)

References (45)
  • 1
    • 2342591455 scopus 로고    scopus 로고
    • The discovery of receptor tyrosine kinases: targets for cancer therapy
    • Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004; 4: 361-370.
    • (2004) Nat Rev Cancer , vol.4 , pp. 361-370
    • Gschwind, A.1    Fischer, O.M.2    Ullrich, A.3
  • 2
    • 22044442973 scopus 로고    scopus 로고
    • Tyrosine kinases as targets for cancer therapy
    • Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353: 172-187.
    • (2005) N Engl J Med , vol.353 , pp. 172-187
    • Krause, D.S.1    Van Etten, R.A.2
  • 4
    • 0041629450 scopus 로고    scopus 로고
    • Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer
    • Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21: 2787-2799.
    • (2003) J Clin Oncol , vol.21 , pp. 2787-2799
    • Mendelsohn, J.1    Baselga, J.2
  • 5
    • 44449127592 scopus 로고    scopus 로고
    • The epidermal growth factor receptor family: biology driving targeted therapeutics
    • Wieduwilt M, Moasser M. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci 2008; 65: 1566-1584.
    • (2008) Cell Mol Life Sci , vol.65 , pp. 1566-1584
    • Wieduwilt, M.1    Moasser, M.2
  • 6
    • 37049183697 scopus 로고
    • Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
    • Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
    • (1987) Science , vol.235 , pp. 177-182
    • Slamon, D.J.1    Clark, G.M.2    Wong, S.G.3
  • 7
    • 34547871259 scopus 로고    scopus 로고
    • Targeting HER proteins in cancer therapy and the role of the non-target HER3
    • Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 2007; 97: 453-457.
    • (2007) Br J Cancer , vol.97 , pp. 453-457
    • Hsieh, A.C.1    Moasser, M.M.2
  • 8
    • 70349556805 scopus 로고    scopus 로고
    • Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4
    • Prickett TD, Agrawal NS, Wei X et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 2009; 41: 1127-1132.
    • (2009) Nat Genet , vol.41 , pp. 1127-1132
    • Prickett, T.D.1    Agrawal, N.S.2    Wei, X.3
  • 9
    • 0030741967 scopus 로고    scopus 로고
    • Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma
    • Gilbertson RJ, Perry RH, Kelly PJ et al. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 1997; 57: 3272-3280.
    • (1997) Cancer Res , vol.57 , pp. 3272-3280
    • Gilbertson, R.J.1    Perry, R.H.2    Kelly, P.J.3
  • 10
    • 0030944455 scopus 로고    scopus 로고
    • ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
    • Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997; 16: 1647-1655.
    • (1997) EMBO J , vol.16 , pp. 1647-1655
    • Graus-Porta, D.1    Beerli, R.R.2    Daly, J.M.3    Hynes, N.E.4
  • 11
    • 33746485766 scopus 로고    scopus 로고
    • Epidermal growth factor receptor targeting in cancer
    • Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006; 33: 369-385.
    • (2006) Semin Oncol , vol.33 , pp. 369-385
    • Mendelsohn, J.1    Baselga, J.2
  • 12
    • 18744384721 scopus 로고    scopus 로고
    • Small molecules with EGFR-TK inhibitor activity
    • Albanell J, Gascon P. Small molecules with EGFR-TK inhibitor activity. Curr Drug Targets 2005; 6: 259-274.
    • (2005) Curr Drug Targets , vol.6 , pp. 259-274
    • Albanell, J.1    Gascon, P.2
  • 13
    • 33750708563 scopus 로고    scopus 로고
    • Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling
    • Wong TW, Lee FY, Yu C et al. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin Cancer Res 2006; 12: 6186-6193.
    • (2006) Clin Cancer Res , vol.12 , pp. 6186-6193
    • Wong, T.W.1    Lee, F.Y.2    Yu, C.3
  • 14
    • 38049025794 scopus 로고    scopus 로고
    • Review: side effects of approved molecular targeted therapies in solid cancers
    • Widakowich C, de Castro G Jr, de Azambuja E et al. Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 2007; 12: 1443-1455.
    • (2007) Oncologist , vol.12 , pp. 1443-1455
    • Widakowich, C.1    de Castro Jr., G.2    de Azambuja, E.3
  • 15
    • 22044445517 scopus 로고    scopus 로고
    • Erlotinib in previously treated non-small-cell lung cancer
    • Shepherd FA, Rodrigues PJ, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132.
    • (2005) N Engl J Med , vol.353 , pp. 123-132
    • Shepherd, F.A.1    Rodrigues, P.J.2    Ciuleanu, T.3
  • 16
    • 33748642331 scopus 로고    scopus 로고
    • Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience
    • Guarneri V, Lenihan DJ, Valero V et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 2006; 24: 4107-4115.
    • (2006) J Clin Oncol , vol.24 , pp. 4107-4115
    • Guarneri, V.1    Lenihan, D.J.2    Valero, V.3
  • 17
    • 34247480545 scopus 로고    scopus 로고
    • Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
    • Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007; 7: 332-344.
    • (2007) Nat Rev Cancer , vol.7 , pp. 332-344
    • Force, T.1    Krause, D.S.2    Van Etten, R.A.3
  • 18
    • 44649165869 scopus 로고    scopus 로고
    • Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor
    • Khakoo AY, Kassiotis CM, Tannir N et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 2008; 112: 2500-2508.
    • (2008) Cancer , vol.112 , pp. 2500-2508
    • Khakoo, A.Y.1    Kassiotis, C.M.2    Tannir, N.3
  • 19
    • 33748987894 scopus 로고    scopus 로고
    • Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma
    • Rojo F, Tabernero J, Albanell J et al. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol 2006; 24: 4309-4316.
    • (2006) J Clin Oncol , vol.24 , pp. 4309-4316
    • Rojo, F.1    Tabernero, J.2    Albanell, J.3
  • 20
    • 17844372539 scopus 로고    scopus 로고
    • Critical update and emerging trends in epidermal growth factor receptor targeting in cancer
    • Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005; 23: 2445-2459.
    • (2005) J Clin Oncol , vol.23 , pp. 2445-2459
    • Baselga, J.1    Arteaga, C.L.2
  • 21
    • 33847273041 scopus 로고    scopus 로고
    • EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences
    • Dassonville O, Bozec A, Fischel JL, Milano G. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences. Crit Rev Oncol Hematol 2007; 62: 53-61.
    • (2007) Crit Rev Oncol Hematol , vol.62 , pp. 53-61
    • Dassonville, O.1    Bozec, A.2    Fischel, J.L.3    Milano, G.4
  • 22
    • 3242720345 scopus 로고    scopus 로고
    • Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
    • Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
    • (2004) N Engl J Med , vol.351 , pp. 337-345
    • Cunningham, D.1    Humblet, Y.2    Siena, S.3
  • 23
    • 0035869407 scopus 로고    scopus 로고
    • Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    • Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
    • (2001) N Engl J Med , vol.344 , pp. 783-792
    • Slamon, D.J.1    Leyland-Jones, B.2    Shak, S.3
  • 24
    • 42649145667 scopus 로고    scopus 로고
    • Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    • Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634.
    • (2008) J Clin Oncol , vol.26 , pp. 1626-1634
    • Amado, R.G.1    Wolf, M.2    Peeters, M.3
  • 25
    • 0035398631 scopus 로고    scopus 로고
    • Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
    • Hidalgo M, Siu LL, Nemunaitis J et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19: 3267-3279.
    • (2001) J Clin Oncol , vol.19 , pp. 3267-3279
    • Hidalgo, M.1    Siu, L.L.2    Nemunaitis, J.3
  • 26
    • 0036569870 scopus 로고    scopus 로고
    • ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial
    • Ranson M, Hammond LA, Ferry D et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002; 20: 2240-2250.
    • (2002) J Clin Oncol , vol.20 , pp. 2240-2250
    • Ranson, M.1    Hammond, L.A.2    Ferry, D.3
  • 27
    • 0037106377 scopus 로고    scopus 로고
    • Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial
    • Herbst RS, Maddox AM, Rothenberg ML et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002; 20: 3815-3825.
    • (2002) J Clin Oncol , vol.20 , pp. 3815-3825
    • Herbst, R.S.1    Maddox, A.M.2    Rothenberg, M.L.3
  • 28
    • 33845886440 scopus 로고    scopus 로고
    • Lapatinib plus capecitabine for HER2-positive advanced breast cancer
    • Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743.
    • (2006) N Engl J Med , vol.355 , pp. 2733-2743
    • Geyer, C.E.1    Forster, J.2    Lindquist, D.3
  • 29
    • 20244378677 scopus 로고    scopus 로고
    • Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer
    • Agus DB, Gordon MS, Taylor C et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005; 23: 2534-2543.
    • (2005) J Clin Oncol , vol.23 , pp. 2534-2543
    • Agus, D.B.1    Gordon, M.S.2    Taylor, C.3
  • 30
    • 33646870539 scopus 로고    scopus 로고
    • A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)
    • Kollmannsberger C, Schittenhelm M, Honecker F et al. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2006; 17: 1007-1013.
    • (2006) Ann Oncol , vol.17 , pp. 1007-1013
    • Kollmannsberger, C.1    Schittenhelm, M.2    Honecker, F.3
  • 31
    • 32944461545 scopus 로고    scopus 로고
    • Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
    • Konecny GE, Pegram MD, Venkatesan N et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006; 66: 1630-1639.
    • (2006) Cancer Res , vol.66 , pp. 1630-1639
    • Konecny, G.E.1    Pegram, M.D.2    Venkatesan, N.3
  • 32
    • 51149117030 scopus 로고    scopus 로고
    • Drug Insight: intracellular inhibitors of HER2-clinical development of lapatinib in breast cancer
    • Cameron DA, Stein S. Drug Insight: intracellular inhibitors of HER2-clinical development of lapatinib in breast cancer. Nat Clin Pract Oncol 2008; 5: 512-520.
    • (2008) Nat Clin Pract Oncol , vol.5 , pp. 512-520
    • Cameron, D.A.1    Stein, S.2
  • 33
    • 23944476155 scopus 로고    scopus 로고
    • Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
    • Burris HA III, Hurwitz HI, Dees EC et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005; 23: 5305-5313.
    • (2005) J Clin Oncol , vol.23 , pp. 5305-5313
    • Burris III, H.A.1    Hurwitz, H.I.2    Dees, E.C.3
  • 34
    • 84901290217 scopus 로고    scopus 로고
    • FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2
    • Ryan Q, Ibrahim A, Cohen MH et al. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 2008; 13: 1114-1119.
    • (2008) Oncologist , vol.13 , pp. 1114-1119
    • Ryan, Q.1    Ibrahim, A.2    Cohen, M.H.3
  • 35
    • 34547470997 scopus 로고    scopus 로고
    • The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272
    • Minami Y, Shimamura T, Shah K et al. The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene 2007; 26: 5023-5027.
    • (2007) Oncogene , vol.26 , pp. 5023-5027
    • Minami, Y.1    Shimamura, T.2    Shah, K.3
  • 36
    • 33746154236 scopus 로고    scopus 로고
    • Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272
    • Shimamura T, Ji H, Minami Y et al. Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res 2006; 66: 6487-6491.
    • (2006) Cancer Res , vol.66 , pp. 6487-6491
    • Shimamura, T.1    Ji, H.2    Minami, Y.3
  • 37
    • 34347208648 scopus 로고    scopus 로고
    • Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy
    • Li D, Shimamura T, Ji H et al. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 2007; 12: 81-93.
    • (2007) Cancer Cell , vol.12 , pp. 81-93
    • Li, D.1    Shimamura, T.2    Ji, H.3
  • 38
    • 34147107009 scopus 로고    scopus 로고
    • Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
    • Sequist LV. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Oncologist 2007; 12: 325-330.
    • (2007) Oncologist , vol.12 , pp. 325-330
    • Sequist, L.V.1
  • 39
    • 33751416678 scopus 로고    scopus 로고
    • HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: preliminary phase 1 results in patients with solid tumors
    • Wong KK, Fracasso PM, Bukowski RM et al. HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: preliminary phase 1 results in patients with solid tumors. J Clin Oncol (Meeting Abstracts) 2006; 24: 3018.
    • (2006) J Clin Oncol (Meeting Abstracts) , vol.24 , pp. 3018
    • Wong, K.K.1    Fracasso, P.M.2    Bukowski, R.M.3
  • 40
    • 77954584507 scopus 로고    scopus 로고
    • Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced nonsmall-cell lung cancer
    • Sequist LV, Besse B, Lynch TJ et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced nonsmall-cell lung cancer. J Clin Oncol 2010; 28: 3076-3083.
    • (2010) J Clin Oncol , vol.28 , pp. 3076-3083
    • Sequist, L.V.1    Besse, B.2    Lynch, T.J.3
  • 41
    • 33751421795 scopus 로고    scopus 로고
    • A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumors
    • Lewis N, Marshall J, Amelsberg A et al. A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 2006; 24: 3091.
    • (2006) J Clin Oncol (Meeting Abstracts) , vol.24 , pp. 3091
    • Lewis, N.1    Marshall, J.2    Amelsberg, A.3
  • 42
    • 77957585027 scopus 로고    scopus 로고
    • Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors
    • Yap TA, Vidal L, Adam J et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 2010; 28: 3965-3972.
    • (2010) J Clin Oncol , vol.28 , pp. 3965-3972
    • Yap, T.A.1    Vidal, L.2    Adam, J.3
  • 43
    • 38049038935 scopus 로고    scopus 로고
    • A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
    • Eskens FA, Mom CH, Planting AS et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer 2008; 98: 80-85.
    • (2008) Br J Cancer , vol.98 , pp. 80-85
    • Eskens, F.A.1    Mom, C.H.2    Planting, A.S.3
  • 44
    • 78649518887 scopus 로고    scopus 로고
    • A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2)
    • Yang C, Shih J, Su W et al. A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2). J Clin Oncol (Meeting Abstracts) 2010; 28: 7521.
    • (2010) J Clin Oncol (Meeting Abstracts) , vol.28 , pp. 7521
    • Yang, C.1    Shih, J.2    Su, W.3
  • 45
    • 77954242530 scopus 로고    scopus 로고
    • Molecular circuits of solid tumors: prognostic and predictive tools for bedside use
    • Ferte C, Andre F, Soria JC. Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. Nat Rev Clin Oncol 2010; 7: 367-380.
    • (2010) Nat Rev Clin Oncol , vol.7 , pp. 367-380
    • Ferte, C.1    Andre, F.2    Soria, J.C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.